Ep. 320 - U.K. Biotech, U.S.-China, Insmed

Merck"s announcement that it is moving its R&D out of the U.K. highlights concerns about the country’s life sciences policies. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the life sciences ecosystem in the U.K., including MHRA CEO Lawrence Tallon’s plans to create a world-class regulatory environment. They also discuss a bill passed by the U.S. House of Representatives that would end most U.S.-China academic research collaborations, and the recent success of 40-year-old biotech Insmed. This episode of BioCentury This Week is sponsored by IQVIA Biotech. View full story: https://www.biocentury.com/article/656997 #biotech #biopharma #pharma #lifescience #MHRA #China #RandD #DrugDevelopment 00:01 - Sponsor Message: IQVIA Biotech 01:25 - U.K. Biopharma 04:40 - Grand Rounds Cambridge 09:45 - SAFE Research Act 18:01 - Spotlight on Insmed 26:32 - Sen. Cassidy"s Vaccine Callout To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text